Tags

Type your tag names separated by a space and hit enter

[Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
Clin Calcium 2010; 20(3):396-407CC

Abstract

Since the aim of the treatment of osteoporosis is to prevent fractures, the first-line drugs must be chosen according to their antifracture efficacies. In postmenopausal women with osteoporosis, alendronate, risedronate, minodronate, and raloxifene are effective in preventing vertebral fractures, and alendronate and risedronate significantly prevent hip fractures. Because the antifracture efficacy of raloxifene against vertebral fractures is considered similar to that of bisphosphonates, the discrimination of raloxifene from bisphosphonates depends on the strategy of doctors (internal medicine, gynecology, and orthopaedics) for preventing vertebral fractures according to the possible side effects of drugs including upper gastrointestinal events, hot flash, and deep vein thromboembolism. Recent reports suggest that patients could be identified who are more responsive to raloxifene than bisphosphonates by evaluating collagen cross-links markers such as homocysteine. Because the incidence of vertebral fractures is higher in Japanese patients, raloxifene plays an important role in the prevention of vertebral fractures in postmenopausal Japanese women with osteoporosis.

Authors+Show Affiliations

Institute for Integrated Sports Medicine, Keio University School of Medicine.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

20190370

Citation

Iwamoto, Jun. "[Effects of SERMs On Bone Health. Discrimination of SERMs From Bisphosphonates in the Treatment of Postmenopausal Osteoporosis]." Clinical Calcium, vol. 20, no. 3, 2010, pp. 396-407.
Iwamoto J. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. Clin Calcium. 2010;20(3):396-407.
Iwamoto, J. (2010). [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. Clinical Calcium, 20(3), pp. 396-407. doi:CliCa1003396407.
Iwamoto J. [Effects of SERMs On Bone Health. Discrimination of SERMs From Bisphosphonates in the Treatment of Postmenopausal Osteoporosis]. Clin Calcium. 2010;20(3):396-407. PubMed PMID: 20190370.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. A1 - Iwamoto,Jun, PY - 2010/3/2/entrez PY - 2010/3/2/pubmed PY - 2010/6/2/medline SP - 396 EP - 407 JF - Clinical calcium JO - Clin Calcium VL - 20 IS - 3 N2 - Since the aim of the treatment of osteoporosis is to prevent fractures, the first-line drugs must be chosen according to their antifracture efficacies. In postmenopausal women with osteoporosis, alendronate, risedronate, minodronate, and raloxifene are effective in preventing vertebral fractures, and alendronate and risedronate significantly prevent hip fractures. Because the antifracture efficacy of raloxifene against vertebral fractures is considered similar to that of bisphosphonates, the discrimination of raloxifene from bisphosphonates depends on the strategy of doctors (internal medicine, gynecology, and orthopaedics) for preventing vertebral fractures according to the possible side effects of drugs including upper gastrointestinal events, hot flash, and deep vein thromboembolism. Recent reports suggest that patients could be identified who are more responsive to raloxifene than bisphosphonates by evaluating collagen cross-links markers such as homocysteine. Because the incidence of vertebral fractures is higher in Japanese patients, raloxifene plays an important role in the prevention of vertebral fractures in postmenopausal Japanese women with osteoporosis. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/20190370/[Effects_of_SERMs_on_bone_health__Discrimination_of_SERMs_from_bisphosphonates_in_the_treatment_of_postmenopausal_osteoporosis]_ L2 - http://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -